Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
trial sector : Transportation and warehousing save search
Skye Bioscience Completes Enrollment of Phase 2a Clinical Trial of SBI-100 Ophthalmic Emulsion in Glaucoma and Ocular Hypertension
Published: 2024-02-26 (Crawled : 12:00) - globenewswire.com
SKYE | $16.865 -2.85% -2.94% 70K
|
Transportation and Warehousing
|
| O: 6.66%
H: 7.43%
C: 6.72%
sbi-100 glaucoma ocular bioscience hypertension trial
Skye Bioscience Receives IND Clearance for Phase 2 Clinical Trial of Nimacimab in Obesity and Chronic Kidney Disease
Published: 2024-01-09 (Crawled : 16:00) - biospace.com/
SKYE | $16.865 -2.85% -2.94% 70K
|
Transportation and Warehousing
|
| O: -7.02%
H: 29.11%
C: 15.56%
SNY | News | $45.395 -1.55% -1.58% 4.4M
|
Health Technology
|
| O: 0.74%
H: 0.0%
C: 0.0%
obesity disease kidney bioscience clearance trial
Skye Bioscience Announces Positive Phase 1 Trial Results for SBI-100 Ophthalmic Emulsion, Its First-in-Class CB1 Agonist Being Developed for the Treatment of Glaucoma
Published: 2023-10-25 (Crawled : 14:00) - biospace.com/
SKYE | $16.865 -2.85% -2.94% 70K
|
Transportation and Warehousing
|
| O: -0.31%
H: 0.0%
C: -23.0%
sbi-100 glaucoma agonist positive bioscience treatment trial results
Skye Bioscience Receives Clinical Site Approvals for Glaucoma Phase 2a Trial
Published: 2023-09-27 (Crawled : 15:30) - biospace.com/
SKYE | $16.865 -2.85% -2.94% 70K
|
Transportation and Warehousing
| Email alert
Add to watchlist
glaucoma bioscience trial
Skye Bioscience Completes Production and Filling of Investigational Drug Material in Preparation for Phase 2a Glaucoma Clinical Trial
Published: 2023-07-06 (Crawled : 16:00) - biospace.com/
SKYE | $16.865 -2.85% -2.94% 70K
|
Transportation and Warehousing
|
| O: -9.87%
H: 19.4%
C: 19.4%
glaucoma drug bioscience trial
Skye Bioscience Completes Enrollment of Phase 1 Clinical Trial of Novel CB1R Agonist, SBI-100 Ophthalmic Emulsion
Published: 2023-06-12 (Crawled : 15:20) - biospace.com/
SKYE | $16.865 -2.85% -2.94% 70K
|
Transportation and Warehousing
|
| O: 0.0%
H: 11.92%
C: 5.3%
sbi-100 bioscience trial
Skye Bioscience Begins Dosing Fifth of Six Cohorts in Phase 1 Clinical Trial of Novel CB1R Agonist
Published: 2023-05-17 (Crawled : 14:20) - biospace.com/
SKYE | $16.865 -2.85% -2.94% 70K
|
Transportation and Warehousing
|
| O: 3.45%
H: 3.33%
C: -3.33%
six agonist bioscience trial
Skye Bioscience Doses Third Cohort of Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion
Published: 2023-03-07 (Crawled : 15:00) - biospace.com/
SKYE | $16.865 -2.85% -2.94% 70K
|
Transportation and Warehousing
|
| O: -9.67%
H: 10.33%
C: 7.01%
sbi-100 trial bioscience ophthalmic emulsion phase 1
Skye Bioscience Doses Second Cohort of Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion
Published: 2023-02-13 (Crawled : 18:00) - biospace.com/
SKYE | $16.865 -2.85% -2.94% 70K
|
Transportation and Warehousing
|
| O: -4.91%
H: 14.13%
C: 0.54%
sbi-100 trial bioscience ophthalmic emulsion phase 1
Skye Bioscience Retains Lexitas Pharma Services as CRO for Phase 2 Trial of SBI-100 Ophthalmic Emulsion
Published: 2023-02-02 (Crawled : 16:00) - biospace.com/
SKYE | $16.865 -2.85% -2.94% 70K
|
Transportation and Warehousing
|
| O: 2.11%
H: 36.6%
C: 29.64%
sbi-100 pharma services trial bioscience phase 2 ophthalmic emulsion
Skye Bioscience Obtains Central IRB Approval for Phase 2 Clinical Trial with SBI-100 Ophthalmic Emulsion
Published: 2023-01-27 (Crawled : 15:00) - biospace.com/
SKYE | $16.865 -2.85% -2.94% 70K
|
Transportation and Warehousing
|
| O: 3.57%
H: 10.0%
C: -1.72%
sbi-100 trial approval bioscience phase 2 ophthalmic emulsion
Skye Bioscience Receives FDA Authorization of Investigational New Drug Application for SBI-100 OE
Published: 2022-12-20 (Crawled : 17:00) - biospace.com/
SKYE | $16.865 -2.85% -2.94% 70K
|
Transportation and Warehousing
|
| O: 4.8%
H: 14.5%
C: -8.4%
sbi-100 fda drug application authorization bioscience
Skye Bioscience Doses First Cohort of Participants in Phase 1 Clinical Trial of SBI-100 Ophthalmic Emulsion
Published: 2022-12-16 (Crawled : 16:00) - biospace.com/
SKYE | $16.865 -2.85% -2.94% 70K
|
Transportation and Warehousing
|
| O: -8.09%
H: 27.2%
C: 8.0%
sbi-100 trial bioscience ophthalmic emulsion phase 1
TSP CLASS ACTION: Hagens Berman, National Trial Attorneys, Encourages Investors in the TuSimple Holdings (TSP) IPO to Contact the Firm's Attorneys, Securities Class Action Filed
Published: 2022-09-07 (Crawled : 14:00) - prnewswire.com
TSP | $0.25 -5.66% 3.96% 0
|
Transportation and Warehousing
|
| O: -1.11%
H: 6.16%
C: 5.88%
trial
TSP INVESTOR ALERT: Hagens Berman, National Trial Attorneys, Encourages Investors in the TuSimple Holdings (TSP) IPO to Contact the Firm's Attorneys, Firm Investigating Possible Securities Law Violations
Published: 2022-08-03 (Crawled : 14:00) - prnewswire.com
TSP | $0.25 -5.66% 3.96% 0
|
Transportation and Warehousing
|
| O: -0.22%
H: 7.89%
C: 6.35%
trial
Skye Bioscience Engages Clinical Trial Site for Phase 1 Study in Agreement with CMAX Clinical Research
Published: 2022-04-28 (Crawled : 20:00) - biospace.com/
SKYE | $16.865 -2.85% -2.94% 70K
|
Transportation and Warehousing
|
| O: -4.86%
H: 7.1%
C: 3.69%
research trial bioscience phase 1
Skye Bioscience Retains Novotech as CRO for Phase 1 Trial of Glaucoma Drug Candidate
Published: 2022-03-03 (Crawled : 17:00) - biospace.com/
SKYE | $16.865 -2.85% -2.94% 70K
|
Transportation and Warehousing
|
| O: 0.0%
H: 7.42%
C: 0.26%
glaucoma drug trial phase 1 bioscience phase 2 phase 3
Sun Country Airlines to Participate in the 2022 Barclays Industrial Select Conference
Published: 2022-02-21 (Crawled : 20:00) - globenewswire.com
SNCY | $14.725 1.13% 1.12% 350K
|
Transportation and Warehousing
|
| O: -0.51%
H: 0.98%
C: -1.6%
air trial conference
Skye Bioscience Reports Positive Results for SBI-100 in GLP Toxicology Study
Published: 2022-02-16 (Crawled : 14:00) - biospace.com/
SKYE | $16.865 -2.85% -2.94% 70K
|
Transportation and Warehousing
|
| O: -2.11%
H: 33.85%
C: 28.62%
sbi-100 positive results 100 report positive bioscience results
Yellow Corporation to Present at Raymond James Diversified Industrials Conference
Published: 2021-08-18 (Crawled : 17:00) - globenewswire.com
YELL | $1.1 -29.03% -44.19% 8.1M
|
Transportation and Warehousing
|
| O: -0.17%
H: 2.24%
C: -1.38%
trial conference presentation
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.